You are running an unsupported browser, please upgrade your browser. Close

Email Subscription

Never miss the latest news and offers - subscribe now!

Never miss the latest news and offers - subscribe now!

Privacy Policy and Cookies

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

Pall Biotech virus safety
Biotech

Virus Safety and Control

Pall Biotech and virus safety

Orthogonal Technologies for Viral Clearance

Many biopharmaceutical therapies, such as mAbs and blood plasma factors, are produced using biological materials. This carries the risk that microorganisms may be unintentionally introduced into the manufacturing process and contaminate the product; these include (amongst others) bacteria, mycobacteria, transmissible spongiform encephalopathy (TSE) agents and viruses, called adventitious agents. In addition to extensive testing during the manufacturing process, in order to demonstrate the absence of adventitious agents, it has to be proven that the manufacturing process is capable of removing them.

 

Introduction of multiple complementary and validated viral clearance steps in the manufacturing process, which inactivate and/or remove potential viral contaminants, are of paramount importance in developing new processes for biopharmaceutical drug manufacturing.

 

An orthogonal approach to virus safety in bioprocessing involves different but complementary techniques, which work together to reduce the risk of virus contamination reaching the final drug product. This may include retentive processes such as virus filtration, adsorptive processes such as chromatography, and inactivation processes under certain conditions such as low pH; that destroy the virus particles. Regulatory bodies like the European Medicines Agency (EMA) and Food and Drug Administration (FDA) require that a minimum of two orthogonal steps for viral clearance need to be employed in the manufacture of therapeutic proteins derived from biological materials. Pall Biotech can provide technology for three orthogonal step options in either batch or continuous processing mode.

 

Pall Biotech Integrated Solutions

 

With over 20 years of experience in providing automated systems for viral clearance, Pall Biotech can provide the knowhow and engineering excellence for an automated system for a single orthogonal viral clearance step, an optimized downstream processing train, or a complete end-to-end solution. Whether it would be a traditional stainless-steel approach, a single-use approach, continuous or hybrid, our integrated solutions can help you find the best choice for viral clearance in your bioprocessing journey.

virus safety and control

Virus Filtration

Established and effective means of removing potentially hazardous virus particles from the drug product
Established and effective means of removing potentially hazardous virus particles from the drug product
Read more

Virus Inactivation

Virus inactivation methods for your production process that will eliminate concerns about infectious agents
Virus inactivation methods for your production process that will eliminate concerns about infectious agents
Read more

Viral Clearance Using Anion Exchange Membranes

Remove virus contamination that binds to the surface of the membrane
Remove virus contamination that binds to the surface of the membrane
Read more

Featured Products

Cadence™ Virus Inactivation System
Biotech

Cadence™ Virus Inactivation System

Product Category: Viral Clearance
Biotech

Product Category: Viral Clearance

Mustang® Q XT Ion Exchange
Biotech

Mustang® Q XT Ion Exchange